×
About 186,726 results

ALLMedicine™ Prostate Cancer Center

Research & Reviews  85,785 results

Cytoplasmic localization of prostate-specific membrane antigen inhibitors may confer ad...
https://doi.org/10.1158/0008-5472.CAN-20-1624
Cancer Research; Matthias J, Engelhardt J et. al.

Feb 24th, 2021 - Targeted imaging and therapy approaches based on novel prostate-specific membrane antigen (PSMA) inhibitors have fundamentally changed the treatment regimen of prostate cancer. However, the exact mechanism of PSMA inhibitor internalization has not...

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostat...
https://doi.org/10.1158/1078-0432.CCR-20-4573
Clinical Cancer Research : an Official Journal of the Ame... Morris MJ, Rowe SP et. al.

Feb 24th, 2021 - Current FDA-approved imaging modalities are inadequate for localizing prostate cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule PSMA-targeted PET radiotracer. CONDOR was a prospective study designed to determin...

Advances in the selection of patients with prostate cancer for active surveillance.
https://doi.org/10.1038/s41585-021-00432-w 10.1016/j.eururo.2009.02.028 10.1016/j.eururo.2013.12.062 10.1001/jama.2018.19941 10.1111/his.13712 10.21037/tau.2018.03.02 10.1016/j.eururo.2016.06.007 10.1016/j.juro.2015.02.2938 10.1001/jamaoncol.2016.0170 10.1001/jama.1994.03510290050036 10.1016/j.eururo.2007.11.057 10.1002/cncr.20586 10.1016/j.juro.2008.11.107 10.1016/j.juro.2017.10.029 10.1016/j.juro.2014.04.013 10.1200/JCO.2002.03.061 10.1016/j.eururo.2012.05.049 10.1016/j.urology.2007.11.094 10.1016/j.urology.2013.12.054 10.1016/j.juro.2013.09.029 10.1002/cncr.32709 10.1016/j.juro.2010.10.057 10.1001/jamaoncol.2017.1879 10.1016/j.eururo.2013.03.033 10.1016/j.juro.2016.06.102 10.1016/j.juro.2018.04.058 10.1200/JCO.2015.62.5764 10.1097/PAS.0000000000000235 10.1016/j.anndiagpath.2015.10.013 10.1038/modpathol.2014.116 10.1016/j.ejca.2016.07.012 10.1016/j.euf.2017.03.004 10.1038/s41391-018-0093-2 10.1007/s00261-016-0975-5 10.1016/S1078-1439(03)00031-0 10.1111/j.1464-410X.2009.08938.x 10.1016/j.eururo.2007.08.006 10.1016/j.juro.2014.02.005 10.1016/j.eururo.2008.11.051 10.1016/S0140-6736(16)32401-1 10.1056/NEJMoa1801993 10.1016/j.eururo.2015.08.052 10.1016/j.juro.2018.05.003 10.1111/bju.13624 10.1038/s41391-018-0111-4 10.1111/bju.14916 10.1097/JU.0000000000000693 10.1016/j.eururo.2019.10.007 10.1016/j.juro.2017.07.070 10.1038/nrurol.2016.26 10.21037/tau.2017.12.26 10.1007/s13402-016-0268-6 10.1016/j.juro.2015.01.091 10.1016/j.purol.2011.09.009 10.1016/j.eururo.2014.07.034 10.1111/bju.14098 10.1111/bju.15101 10.1016/j.eururo.2014.10.021 10.1016/j.eururo.2016.11.017 10.1001/jamaoncol.2017.0177 10.1158/1078-0432.CCR-12-3283 10.1038/s41391-018-0124-z 10.1038/pcan.2017.16 10.1016/j.eururo.2016.04.012 10.1001/jamaoncol.2016.0097 10.1016/j.eururo.2018.08.019 10.1016/j.juro.2012.08.219 10.2741/4191 10.1002/path.2559 10.1016/j.juro.2015.09.072 10.1200/JCO.2012.46.4396 10.2217/pme-2019-0084 10.1111/bju.12789 10.1002/cncr.30665 10.1038/s41391-019-0167-9 10.1016/j.eururo.2014.05.004 10.1200/JCO.19.02267 10.1016/j.juro.2014.09.094 10.1016/j.juro.2010.09.095
Nature Reviews. Urology; Liu JL, Patel HD et. al.

Feb 24th, 2021 - Early identification and management of prostate cancer completely changed with the discovery of prostate-specific antigen. However, improved detection has also led to overdiagnosis and consequently overtreatment of patients with low-risk disease. ...

see more →

Guidelines  391 results

ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but...
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,

Dec 14th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 22nd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 22nd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...

American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Relate...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB

Sep 6th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|

Optimizing the management of castration-resistant prostate cancer patients: A practical...
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.

Aug 11th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...

see more →

Drugs  337 results see all →

Clinicaltrials.gov  93,515 results

Cytoplasmic localization of prostate-specific membrane antigen inhibitors may confer ad...
https://doi.org/10.1158/0008-5472.CAN-20-1624
Cancer Research; Matthias J, Engelhardt J et. al.

Feb 24th, 2021 - Targeted imaging and therapy approaches based on novel prostate-specific membrane antigen (PSMA) inhibitors have fundamentally changed the treatment regimen of prostate cancer. However, the exact mechanism of PSMA inhibitor internalization has not...

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostat...
https://doi.org/10.1158/1078-0432.CCR-20-4573
Clinical Cancer Research : an Official Journal of the Ame... Morris MJ, Rowe SP et. al.

Feb 24th, 2021 - Current FDA-approved imaging modalities are inadequate for localizing prostate cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule PSMA-targeted PET radiotracer. CONDOR was a prospective study designed to determin...

Advances in the selection of patients with prostate cancer for active surveillance.
https://doi.org/10.1038/s41585-021-00432-w 10.1016/j.eururo.2009.02.028 10.1016/j.eururo.2013.12.062 10.1001/jama.2018.19941 10.1111/his.13712 10.21037/tau.2018.03.02 10.1016/j.eururo.2016.06.007 10.1016/j.juro.2015.02.2938 10.1001/jamaoncol.2016.0170 10.1001/jama.1994.03510290050036 10.1016/j.eururo.2007.11.057 10.1002/cncr.20586 10.1016/j.juro.2008.11.107 10.1016/j.juro.2017.10.029 10.1016/j.juro.2014.04.013 10.1200/JCO.2002.03.061 10.1016/j.eururo.2012.05.049 10.1016/j.urology.2007.11.094 10.1016/j.urology.2013.12.054 10.1016/j.juro.2013.09.029 10.1002/cncr.32709 10.1016/j.juro.2010.10.057 10.1001/jamaoncol.2017.1879 10.1016/j.eururo.2013.03.033 10.1016/j.juro.2016.06.102 10.1016/j.juro.2018.04.058 10.1200/JCO.2015.62.5764 10.1097/PAS.0000000000000235 10.1016/j.anndiagpath.2015.10.013 10.1038/modpathol.2014.116 10.1016/j.ejca.2016.07.012 10.1016/j.euf.2017.03.004 10.1038/s41391-018-0093-2 10.1007/s00261-016-0975-5 10.1016/S1078-1439(03)00031-0 10.1111/j.1464-410X.2009.08938.x 10.1016/j.eururo.2007.08.006 10.1016/j.juro.2014.02.005 10.1016/j.eururo.2008.11.051 10.1016/S0140-6736(16)32401-1 10.1056/NEJMoa1801993 10.1016/j.eururo.2015.08.052 10.1016/j.juro.2018.05.003 10.1111/bju.13624 10.1038/s41391-018-0111-4 10.1111/bju.14916 10.1097/JU.0000000000000693 10.1016/j.eururo.2019.10.007 10.1016/j.juro.2017.07.070 10.1038/nrurol.2016.26 10.21037/tau.2017.12.26 10.1007/s13402-016-0268-6 10.1016/j.juro.2015.01.091 10.1016/j.purol.2011.09.009 10.1016/j.eururo.2014.07.034 10.1111/bju.14098 10.1111/bju.15101 10.1016/j.eururo.2014.10.021 10.1016/j.eururo.2016.11.017 10.1001/jamaoncol.2017.0177 10.1158/1078-0432.CCR-12-3283 10.1038/s41391-018-0124-z 10.1038/pcan.2017.16 10.1016/j.eururo.2016.04.012 10.1001/jamaoncol.2016.0097 10.1016/j.eururo.2018.08.019 10.1016/j.juro.2012.08.219 10.2741/4191 10.1002/path.2559 10.1016/j.juro.2015.09.072 10.1200/JCO.2012.46.4396 10.2217/pme-2019-0084 10.1111/bju.12789 10.1002/cncr.30665 10.1038/s41391-019-0167-9 10.1016/j.eururo.2014.05.004 10.1200/JCO.19.02267 10.1016/j.juro.2014.09.094 10.1016/j.juro.2010.09.095
Nature Reviews. Urology; Liu JL, Patel HD et. al.

Feb 24th, 2021 - Early identification and management of prostate cancer completely changed with the discovery of prostate-specific antigen. However, improved detection has also led to overdiagnosis and consequently overtreatment of patients with low-risk disease. ...

see more →

News  6,531 results

No Benefit of Dose-Intensified Salvage Radiation for Prostate Cancer Recurrence
https://www.medscape.com/viewarticle/946211

Feb 23rd, 2021 - NEW YORK (Reuters Health) - Dose-intensified salvage radiotherapy is not superior to conventional dose salvage RT and is associated with increased late rectal toxicity in patients with biochemical recurrence of prostate cancer after prostatectomy,...

5 Challenges to Conventional Wisdom in Prostate Cancer
https://www.medscape.com/viewarticle/945928

Feb 22nd, 2021 - Patients with prostate cancer have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices...

Quick MRI Scan for Routine Prostate Cancer Screening?
https://www.medscape.com/viewarticle/946187

Feb 21st, 2021 - Could imaging be used for routine screening for prostate cancer in healthy men — similar to mammography for breast cancer screening? A quick scan — with 15-minute, contrast-free MRI — detected more clinically significant prostate tumors than the u...

Study Shows UK Sniffer Dogs Have a Nose for Prostate Cancer
https://www.medscape.com/viewarticle/946111

Feb 18th, 2021 - The results of a trial led by Medical Detection Dogs in Milton Keynes suggest that trained dogs can detect advanced prostate cancer in urine samples with high specificity and sensitivity. The study, published in  PLoS One,  tested the clinical fea...

Relugolix Confirmed to Cut Menstrual Bleed by Half in Most Women With Fibroids
https://www.medscape.com/viewarticle/945995

Feb 17th, 2021 - (Reuters Health) - Daily relugolix therapy cuts menstrual bleeding by at least half without affecting bone density in 71% of women with uterine fibroids, according to results from the LIBERTY 2 trial, published by The New England Journal of Medici...

see more →

Patient Education  167 results see all →